JP2024529044A - レプトスピラ病毒性調節タンパク質とその使用 - Google Patents

レプトスピラ病毒性調節タンパク質とその使用 Download PDF

Info

Publication number
JP2024529044A
JP2024529044A JP2024507020A JP2024507020A JP2024529044A JP 2024529044 A JP2024529044 A JP 2024529044A JP 2024507020 A JP2024507020 A JP 2024507020A JP 2024507020 A JP2024507020 A JP 2024507020A JP 2024529044 A JP2024529044 A JP 2024529044A
Authority
JP
Japan
Prior art keywords
seq
lic
lmanv2
protein
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024507020A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529044A5 (enExample
Inventor
ビネッツ ジョセフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2024529044A publication Critical patent/JP2024529044A/ja
Publication of JP2024529044A5 publication Critical patent/JP2024529044A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024507020A 2021-08-06 2022-08-05 レプトスピラ病毒性調節タンパク質とその使用 Pending JP2024529044A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163230244P 2021-08-06 2021-08-06
US63/230,244 2021-08-06
PCT/US2022/074601 WO2023015290A1 (en) 2021-08-06 2022-08-05 Leptospiral virulence modulating proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2024529044A true JP2024529044A (ja) 2024-08-01
JP2024529044A5 JP2024529044A5 (enExample) 2025-08-14

Family

ID=85156339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024507020A Pending JP2024529044A (ja) 2021-08-06 2022-08-05 レプトスピラ病毒性調節タンパク質とその使用

Country Status (6)

Country Link
US (1) US20240277823A1 (enExample)
EP (1) EP4380608A4 (enExample)
JP (1) JP2024529044A (enExample)
CN (1) CN117979992A (enExample)
AU (1) AU2022323324A1 (enExample)
WO (1) WO2023015290A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025208019A1 (en) * 2024-03-29 2025-10-02 Yale University Leptospiral virulence modulating protein epitopes and uses thereof
WO2026006400A2 (en) * 2024-06-25 2026-01-02 Luna Bioscience, Inc. A virulence modifying protein-based recombinant vaccine and rapid diagnostic assay for leptospira

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700263A1 (ru) * 2004-07-01 2007-06-29 Кебенхавнс Университет Способ лечения и профилактики рассеянного склероза путём лечения лептоспирозной инфекции
AU2016219787B2 (en) * 2015-02-20 2019-05-30 Calixar Leptospira immunoprotective proteins and methods of identification and use thereof
EP4100050A4 (en) * 2020-02-07 2024-07-10 Yale University Leptospiral proteins and uses thereof

Also Published As

Publication number Publication date
WO2023015290A1 (en) 2023-02-09
AU2022323324A1 (en) 2024-03-21
CN117979992A (zh) 2024-05-03
EP4380608A4 (en) 2026-04-15
EP4380608A1 (en) 2024-06-12
US20240277823A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
US8846058B2 (en) Shiga toxoid chimeric proteins
US10105412B2 (en) Vaccines and compositions against Streptococcus pneumoniae
JP6126993B2 (ja) 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対するワクチン及び組成物
US20150197558A1 (en) Binding moieties for biofilm remediation
JP2009515831A (ja) ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物
CA2884918C (en) Salmonid alphavirus and uses thereof
JP6894237B2 (ja) 変異体ブドウ球菌抗原
CN114423448A (zh) 疫苗组合物和选择抗原的方法
US20240277823A1 (en) Leptospiral virulence modulating proteins and uses thereof
JP2015529677A (ja) ワクチンとしてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅポリペプチド
JP2023025066A (ja) ワクチン構築物およびブドウ球菌感染症に対するその使用
EA025831B1 (ru) Композиции из hyr1-производных и способы лечения ими
US20130101613A1 (en) Protective proteins of s. agalactiae, combinations thereof and methods of using the same
US12595287B2 (en) Leptospiral proteins and uses thereof
US10646561B2 (en) Compositions and methods for using Salmonella typhi toxin to induce or enhance an immune response
JP2024512751A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓワクチン組成物
US10335477B2 (en) Compositions and methods for diagnosing, preventing and treating Salmonella typhi and Salmonella paratyphi infection
HK40106181A (en) Leptospiral virulence modulating proteins and uses thereof
US20180153990A1 (en) Pca1 protein and methods of treating pneumocystis pneumonia infection
US20090162369A1 (en) Synthetic chimeric peptides
WO2025208019A1 (en) Leptospiral virulence modulating protein epitopes and uses thereof
EP3450556B1 (en) Peptide inhibiting colonization by pathogenic bacteria, and colonization inhibitor including same
Larsen et al. Functionally fused antibodies—A novel adjuvant fusion system
Badten et al. Evaluation of highly conserved
HK1172254A (en) Vaccines and compositions against streptococcus pneumoniae

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250805